JLE

Médecine thérapeutique / Pédiatrie

MENU

Vaccination against invasive meningococcal B infections: Real-life data. Based on communications at the 2020 European Society of Pediatric Infectious Diseases (ESPID) Congress Volume 23, issue 1, Janvier-Février-Mars 2021

Author
Centre Hospitalier de Versailles, 177 Rue de Versailles, 78150 Le Chesnay-Rocquencourt
* Correspondance

Effectiveness of the four-component meningococcal B protein vaccine (4MenB) were presented at the 2020 European Society of Pediatric Infectious Diseases (ESPID) Congress.

Three years after its introduction in the infant's routine immunization schedules in the United Kingdom, the number of serogroup B invasive meningococcal disease (IMD) cases has been reduced by 75% in this age group. The Italian experience demonstrated the importance of early initiation of the vaccine schedule (at 2 months vs 7 months). In Portugal, a case-control study found an 82% reduction in serogroup B (IMD) after at least one dose of 4MenB vaccine. Vaccination of 24,000 adolescents with two doses of 4MenB in South Australia resulted in a 71% reduction in cases in this population, with no effect on pharyngeal carriage.

In view of the very favorable benefit/risk ratio of this vaccination, the French pediatric societies are asking for a recommendation and therefore a reimbursement of meningococcal B vaccination for all infants.